The changes to ongoing trials run by Moderna and Pfizer and its German partner BioNTech could delay the availability of the vaccine to children between the ages of 5 and 11 beyond the hoped-for timeline of early fall, although it is unclear by how much.
FDA asks Pfizer, Moderna to test their vaccines in more children to help rule out safety issues
